Outcomes of head and neck cancer management from two cancer centres in Southern and Northern Europe during the first wave of COVID-19.
Tumori
; 108(3): 230-239, 2022 Jun.
Article
in English
| MEDLINE | ID: covidwho-1181055
ABSTRACT
OBJECTIVE:
To describe the approach and outcomes from two cancer centres in Southern and Northern Europe during the first wave of coronavirus disease 2019 (COVID-19) of patients with head and neck cancer (HNC).METHODS:
Data collection was performed on a retrospective cohort of patients surgically treated for primary HNC between March and May 2020, using data from two tertiary hospitals the European Institute of Oncology (Milan) and Guy's & St Thomas' NHS Foundation Trust (London).RESULTS:
We included 77 patients with HNC. More patients with COVID-19 were taking angiotensin-converting enzyme (ACE) inhibitors and had Clavien-Dindo Classification grade I compared to negative patients, respectively (60% vs 22% [p = 0.058] and 40% vs 8% [p = 0.025]). Multivariate logistic regression analyses confirmed our data (p = 0.05 and 0.03, respectively). Sex and age were statistically significantly different (p = 0.05 and <0.001 respectively), showing more male patients (75% vs 53.66%, respectively) and more elderly patients in Italy than in the United Kingdom (patients aged >63 years 69.44% vs 29.27%).CONCLUSIONS:
This study presents a large cohort of patients with HNC with nasopharyngeal swab during the first peak of the COVID-19 pandemic in Europe. Patients with HNC with COVID-19 appeared more likely to develop postsurgical complications and to be taking ACE inhibitors. The preventive measures adopted guaranteed the continuation of therapeutic surgical intervention.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Head and Neck Neoplasms
Type of study:
Cohort study
/
Observational study
/
Prognostic study
Limits:
Aged
/
Humans
/
Male
Country/Region as subject:
Europa
Language:
English
Journal:
Tumori
Year:
2022
Document Type:
Article
Affiliation country:
03008916211007927
Similar
MEDLINE
...
LILACS
LIS